Physician profile
Joseph Vitale
NPI 1205845427
$7,537.58
in general payments reported to CMS, 2019-2025
58 companies · $800 in 2025
The $800 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,500 · 2020: $1,412 · 2021: $1,183 · 2022: $713 · 2023: $727 · 2024: $1,201 · 2025: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,709 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,708.78 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,376.22 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $840.28 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $763.17 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $589.23 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Glaxosmithkline, LLC. | $573.20 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $386.65 | 2019-2025 | Jardiance, Zepbound |
| Abbvie INC. | $320.55 | 2020-2025 | Linzess, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $285.53 | 2020-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $169.18 | 2021-2024 | |
| Ironwood Pharmaceuticals, INC | $139.07 | 2019-2024 | |
| Amarin Pharma, INC. | $137.31 | 2019-2023 | |
| Genzyme Corporation | $130.20 | 2024 | |
| Esperion Therapeutics, INC. | $128.02 | 2020-2024 | Nexletol |
| Exact Sciences Corporation | $116.16 | 2023-2025 | Cologuard Collection Kit |
| Allergan, INC. | $110.00 | 2019-2020 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Vitale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.